We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Today, the U.S. Food and Drug Administration (FDA) permitted the marketing of the Dermapace System, the first shock wave device intended to treat diabetic foot ulcers.